Download PDF
Thromb Haemost 1990; 63(03): 361-366
DOI: 10.1055/s-0038-1645047
Original Article
Schattauer GmbH Stuttgart

Contribution of Platelets to Increased Plasminogen Activator Inhibitor Type 1 in Severe Preeclampsia

Juan Gilabert
1   The Department of Obstetrics and Gynecology, Hospital “La Fe”, Valencia, Spain
,
Amparo Estellés
2   The Research Center, Hospital “La Fe”, Valencia, Spain
,
Justo Aznar
3   The Department of Clinical Pathology, Hospital “La Fe”, Valencia, Spain
,
Francisco España
2   The Research Center, Hospital “La Fe”, Valencia, Spain
,
Cristina Andrés
2   The Research Center, Hospital “La Fe”, Valencia, Spain
,
Teresa Santos
2   The Research Center, Hospital “La Fe”, Valencia, Spain
,
Juana Vallés
2   The Research Center, Hospital “La Fe”, Valencia, Spain
› Author Affiliations
Further Information

Publication History

Received 13 July 1989

Accepted after revision 23 January 1990

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Plasminogen activator inhibitor activity and antigen were evaluated in plasma, serum and platelet lysate in patients with severe preeclampsia (n = 12), and in normal pregnant women (n = 21). Other parameters, including β-thromboglobulin and platelet count, were also evaluated. A significant increase (p <0.05) in β-thromboglobulin was observed in platelet poor plasma of preeclamptic women when compared with that of normal pregnant women, and the platelet count was lower in the preeclamptic group than in the normal pregnant group. A significant increase in plasminogen activator inhibitor activity and antigen was observed in platelet poor plasma of the preeclamptic group as compared with normal pregnant women, whereas platelet lysate from preeclamptic women showed a significant decrease in both plasminogen activator inhibitor activity and antigen as compared with that of normal pregnant women. No correlation between β-thromboglobulin and plasminogen activator inhibitor type 1 antigen in platelet poor plasma was observed, but a significant inverse correlation (r = −0.78, p <0.05) between β-thromboglobulin in platelet poor plasma and plasminogen activator inhibitor-1 antigen in platelet lysate was obtained in preeclamptic patients. However, in platelet poor plasmas obtained from normal platelet rich plasmas activated with thrombin (0.1 IU/ml, 37° C, 1 min), an increase of about 300 ng/ ml in β-thromboglobulin was observed while the increase in plasminogen activator inhibitor was only 4 ng/ml. It is concluded that the contribution of platelet plasminogen activator inhibitor-1 to the increase in plasma plasminogen activator inhibitor-1 levels in preeclamptic patients is negligible but the possibility that intravascular platelet activation indirectly contributes “in vivo” to the increase in plasma plasminogen activator inhibitor-1 levels in severe preeclampsia patients cannot be ruled out.

 

  • References

  • 1 Hathaway W, Bonnar J. Hemostatic alterations in hypertensive and placental insufficiency disorders of pregnancy. In: Hemostatic Disorders of the Pregnant Woman and Newborn Infant Hathaway W, Bonnar J. (eds) John Wiley & Sons; New York: 1987: 185-201
  • 2 Inglis TC M, Stuart J, George AJ, Davies HJ. Haemostatic and rheological changes in normal pregnancy and preeclampsia. Br J Haematol 1982; 50: 461-5
    CrossrefPubMedGoogle Scholar
  • 3 Graeff H, Von Hugo R, Shrock R. Recent aspects of hemostasis hematology and hemorrheology in preeclampsia-eclampsia. Eur J Obstet Gynec Reprod Biol 1984; 17: 91-102
    CrossrefPubMedGoogle Scholar
  • 4 Pritchard JA, MacDonald PC, Gant NF. Hypertensive disorders in pregnancy. In: Williams-Obstetrics. Appleton Century Crofts New York: 1980: 665-700
  • 5 Maki M. Coagulation, fibrinolysis, platelet and kining forming systems during toxemia of pregnancy. Biol Res Pregnancy 1983; 4: 152-4
    PubMedGoogle Scholar
  • 6 Gilabert J, Fernández JA, España F, Aznar J, Estellés A. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988; 49: 319-29
    CrossrefPubMedGoogle Scholar
  • 7 Friedman SA. Preeclampsia: A review of the role of prostaglandins. Obstet Gynecol 1988; 71: 122-37
    PubMedGoogle Scholar
  • 8 Sihai BM, Anderson GD, McGubbin JH. Eclampsia II. Clinical Significance of laboratory finding. Obstet Gynecol 1982 59. 153-7
    PubMedGoogle Scholar
  • 9 Wiman B, Csemiczky G, Marsk L, Robbe H. The fast inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemostas 1984; 52: 124-6
    PubMedGoogle Scholar
  • 10 Terao T, Kobayashi T. The role of placental urokinase inhibitor in toxemia of pregnancy. Biol Res Pregnancy 1983; 4: 145-51
    PubMedGoogle Scholar
  • 11 Aznar J, Gilabert J, Estellϩs A, Espana F. Fibrinolytic activity and protein C in preeclampsia. Thromb Haemostas 1986; 55: 314-7
    PubMedGoogle Scholar
  • 12 Estellϩs A, Gilabert J, Espaϱa F, Aznar J, Gómez-Lechón MJ. Fibrinolysis in preeclampsia. Fibrinolysis 1987; 1: 209-13
    PubMedGoogle Scholar
  • 13 Collen D. Report of the meeting of the subcommittee on fibrinolysis. Jerusalem, Israel: June 2 1986 Thromb Haemostas 1986 56. 415-6
    PubMedGoogle Scholar
  • 14 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemostas Thromb 1988; 9: 87-115
    PubMedGoogle Scholar
  • 15 Van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-21
    PubMedGoogle Scholar
  • 16 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann E. Demonstration of fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13
    PubMedGoogle Scholar
  • 17 Erickson LA, Hekman CM, Loskutoff DJ. The primary plasminogen activator inhibitors in endothelial cells platelet, serum and plasma are immunologically related. Proc Natl Acad Sci USA 1985; 82: 8710-4
    CrossrefPubMedGoogle Scholar
  • 18 Booth NA, Anderson JA, Bennett B. Platelets release protein which inhibits plasminogen activator. J Clin Pathol 1985; 38: 825-30
    CrossrefPubMedGoogle Scholar
  • 19 Astedt B, Lecander I, Ny T. The placental type plasminogen activator inhibitor PAI-2. Fibrinolysis 1987; 1: 203-8
    PubMedGoogle Scholar
  • 20 Lecander I, Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986; 62: 221-8
    CrossrefPubMedGoogle Scholar
  • 21 Heeb MJ, España F, Geiger M, Collen D, Stump DC, Griffin JH. Immunological identity of heparin dependent plasma and urinary protein C inhibitor and plasminogen activator inhibilui-3. J Biol Chem 1987; 262: 15813-6
    PubMedGoogle Scholar
  • 22 Scott ZW, Bergman BL, Bajpai A, Hersh RT, Rodriguez H, Jones BN, Barreda C, Watts S, Baker JB. Protease nexin: properties and modified purification procedure. J Biol Chem 1985; 260: 7029-34
    PubMedGoogle Scholar
  • 23 Kruithof EK O, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemostas 1988; 59: 7-12
    PubMedGoogle Scholar
  • 24 Kruithof EK O, Tran-Thang C, Gudinchet A, Havert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitor. Blood 1987; 69: 460-6
    PubMedGoogle Scholar
  • 25 Lecander I, Nilsson IM, Asted B. Depression of plasminogen activator activity during pregnancy by the placental inhibiloi PAI-2. Fibrinolysis 1988; 2: 165-7
    PubMedGoogle Scholar
  • 26 Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schlccf RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-8
    PubMedGoogle Scholar
  • 27 de Boer K, Lecander J, Ten Cate JW, Bom JJ J, Treffers PE. Placental type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988; 158: 518-22
    CrossrefPubMedGoogle Scholar
  • 28 O’Brien WF, Saba HZ, Knuppel RA, Scerbo JC, Cohen GR. Alterations in platelet concentration and aggregation in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1986; 155: 486-9
    CrossrefPubMedGoogle Scholar
  • 29 Borok Z, Weitz J, Owen J, Auerbach M, Nossel HL. Fibrinogen proteolysis and platelet granule release in preeclampsia/eclampsia. Blood 1984; 63: 525-31
    PubMedGoogle Scholar
  • 1 Socol M, Weiner C, Luis E, Rehnberg K, Rossi E. Platelet activation in preeclampsia. Am J Obstet Gynecol 1985; 15: 494-7
    PubMedGoogle Scholar
  • 31 Nilsson IM, Felding P, Lecander I, Lenner C, Asted B. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. Br J Haematol 1986; 62: 215-20
    CrossrefPubMedGoogle Scholar
  • 32 Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of culture bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987; 70: 721-8
    PubMedGoogle Scholar
  • 33 Ballegeer V, Spitz B, Kieckens L, Moreau H, Van Assche A, Collen D. Predictive value of increased plasma levels of fibronectine in gestational hypertension. Am J Obstet Gynecol 1989; 161: 432-6
    CrossrefPubMedGoogle Scholar
  • 34 Booth NA, Simpson AD, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-33
    CrossrefPubMedGoogle Scholar
  • 35 Declerk PJ, Alessi MC, Verstrekin M, Kruithof EK O, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5
    PubMedGoogle Scholar
  • 36 Kruithof EK O, Nicoloso G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-53
    PubMedGoogle Scholar
  • 37 Schleef RR, Loskutoff DJ. Fibrinolytic system of vascular endothelial cells. Haemostasis 1988; 18: 328-41
    PubMedGoogle Scholar